Loading

Please wait...

Apidra

Generic Name: insulin glulisine (IN su lin GLOO lis een)
Brand Names: Apidra
Apidra is used to treat type 1 (insulin-dependent) diabetes in adults. Learn about side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Apidra

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Apidra is an injection that contains insulin glulisine. Insulin is a hormone that works by lowering levels of glucose (sugar) in the blood. Insulin glulisine is a fast-acting insulin that starts to work about 15 minutes after injection, peaks in about 1 hour, and keeps working for 2 to 4 hours. Apidra is used to improve blood sugar control in adults and children with diabetes mellitus. Apidra is used to treat type 1 or type 2 diabetes in adults, and type 1 diabetes children who are at least 4 years old. Learn more

Apidra Side Effects

Apidra Side Effects

Note: This document contains side effect information about insulin glulisine. Some of the dosage forms listed on this page may not apply to the brand name Apidra.

For the Consumer

Applies to insulin glulisine: parenteral injection

Side effects include:

Hypoglycemia, systemic hypersensitivity, injection site reaction.

For Healthcare Professionals

Applies to insulin glulisine: injectable solution, subcutaneous solution

General

The most common adverse reactions reported include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash.

Metabolic

Common (1% to 10%): Hypoglycemia, hypoglycemic seizure

Frequency not reported: Weight gain

Hypersensitivity

In clinical trials of ups to 12 months duration, potential systemic allergic reactions were reported in 4.3% (79 of 1833) patients receiving insulin glulisine (the active ingredient contained in Apidra) compared with 3.8% (58 of 1524) patients receiving comparator short-acting insulins. Permanent discontinuation occurred in 1 patient receiving insulin glulisine.

Common (1% to 10%): Local hypersensitivity reactions (redness, swelling, and itching at injection site) Uncommon (0.1% to 1%): Systemic allergic reactions including urticaria, chest tightness, dyspnea, allergic dermatitis, and pruritus

Frequency not reported: Anaphylaxis

Local

Among patients using continuous subcutaneous insulin infusion pumps, the rates of catheter occlusions and infusion site reactions were similar with insulin glulisine (the active ingredient contained in Apidra) compared with insulin aspart.

Common (1% to 10%): Infusion site reactions

Very rare (less than 0.01%): Catheter occlusions

Cardiovascular

Common (1% to 10%): Peripheral edema, hypertension

Gastrointestinal

Common (1% to 10%): Diarrhea, pharyngitis, vomiting, nausea

Dermatologic

Rare (less than 0.1%): Lipodystrophy

Immunologic

Common (1% to 10%): Influenza

Respiratory

Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection, sinusitis, bronchitis

Musculoskeletal

Common (1% to 10%): Arthralgia, back pain

Nervous system

Common (1% to 10%): Headache

Genitourinary

Common (1% to 10%): Urinary tract infection

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Apidra